Idalopirdine Clinical data Other names Lu-AE-58054 ATC code Identifiers
2-(6-Fluoro-1 H-indol-3-yl)- N-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)ethanamine CAS Number PubChem CID ChemSpider UNII KEGG ChEMBL ECHA InfoCard 100.245.270 Chemical and physical data Formula C 20 H 19 F 5 N 2 O Molar mass g·mol 398.377 −1 3D model ( JSmol)
(what is this?) (verify) Idalopirdine ( INN) (code names Lu AE58054,) is a potent and selective 5-HT 6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia.  As of October 2013 it is in  phase III clinical trials.
A phase III trial of two different daily doses of Lu AE58054 on top of 10 mg of
donepezil for mild-to-moderate Alzheimer's failed to meet its primary endpoint with either dose. Two further phase III trials failed too, the company confirmed in early 2017. 
See also [ edit ]
References [ edit ]
External links [ edit ]